Medacta Group SA Announces AGM Results with Full Approval of Proposals

In a recent announcement, Medacta Group SA confirmed that all proposals presented by the Board of Directors were approved during their Annual General Meeting held on May 7, 2024. Significant approvals included a CHF 11.0 million dividend payment, equating to CHF 0.55 per share. This will be distributed equally from available earnings and accumulated capital contribution reserves.

The AGM, which saw physical participation from shareholders, was conducted at the company's premises in Rancate, Switzerland. A total of 17,976,115 shares were represented, accounting for approximately 89.88% of the company’s share capital. Dr. Alberto Siccardi was re-elected as the Chairman of the Board of Directors, along with other board members for another one-year term.

Other approved matters included the annual financial reports for 2023, non-financial matters report, and the 2023 remuneration report. Further approvals covered the appropriation of earnings, discharge of board members and executives, re-election of the independent proxy and auditors, and the compensation for board members and executives for the upcoming period.